Corient Private Wealth
ROIV icon

Corient Private Wealth’s Roivant Sciences ROIV Stock Holding History

Corient Private Wealth’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$374K Buy
10,562
+2,044
+24% +$60.4K ﹤0.01% 2410
2026
Q1 		$208K Buy
+8,518
New +$219K ﹤0.01% 2537

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Corient Private Wealth's ROIV Position: Q2 2026 in Review

Corient Private Wealth increased its Roivant Sciences (ROIV) stake by 24% in Q2 2026, buying an estimated $60.4K and bringing the position to 10,562 shares worth $374K. The position accounts for ﹤0.01% of the portfolio, ranked #2410.

Corient Private Wealth first reported a position in ROIV in Q1 2026 and has held it in 2 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Corient Private Wealth held 10,562 shares of Roivant Sciences worth $374K as of Q2 2026.
  • Corient Private Wealth bought 2,044 Roivant Sciences shares in Q2 2026, an estimated $60.4K.
  • Roivant Sciences made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2410 holding.
  • Corient Private Wealth first reported a position in Roivant Sciences in Q1 2026 and has held it in 2 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.